- CA$31.79m
- CA$30.13m
- CA$37.42m
- 99
- 83
- 43
- 89
Annual cashflow statement for Biorem, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2.09 | 1.3 | 1.61 | 2.18 | 3.04 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.063 | 0.059 | 0.133 | 0.212 | 0.226 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.322 | 1.7 | -0.736 | -2.74 | -0.442 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 3.34 | 3.78 | 1.44 | 0.49 | 3.69 |
| Capital Expenditures | -0.342 | -0.076 | -0.203 | -0.553 | -0.372 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.342 | -0.076 | -0.203 | -0.553 | -0.372 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.2 | -7.56 | -0.952 | -1.33 | -0.572 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.4 | -4.4 | -0.696 | -1.48 | 2.92 |